In addition, immunomodulatory agents for in vivo iTreg generation can be considered such as hormone erythropoietin, as its application to patients with chronic kidney disease resulted in an increase of Tregs after 6 months of treatment. The gene discussed is EPO; the disease is chronic kidney disease.